Trial
NCT04762511
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Herpes Simplex
Intervention
Lower dose formulation of HSV vaccine (GSK4108771A)
Why stopped
To enable development of an enhanced version of the vaccine
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-28